Publications by authors named "Robyn Du"
Purpose: Plasma circulating tumor HPV DNA (ctHPVDNA) persistence after curative-intent treatment may identify patients with HPV-positive cancers at risk for recurrence. Technical validation is required for use as an integral biomarker in a prospective clinical trial.
Methods: Development and analytical validation of a digital droplet PCR assay for detection and quantification of 13 high-risk HPV types (i.
Article Synopsis
- - Drug resistance in EGFR-mutant non-small cell lung cancer (NSCLC) is complicated by mechanisms like pathway reactivation and fusion of receptor tyrosine kinases (RTKs), leading to challenges in treatment with tyrosine kinase inhibitors (TKIs).
- - A study involving multiple institutions analyzed 27 patients with RTK fusions identified through genetic testing, focusing on their response to dual TKI therapy, with results showing a 24% objective response rate and an 80% disease control rate overall.
- - The majority of patients had ALK or RET fusions, and those who received dual TKI treatment had a slightly lower response rate (21.4%) but no new side effects were reported, suggesting this approach
Article Synopsis
- Amivantamab-vmjw is a bispecific antibody approved for treating advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations, but its safety and efficacy in other EGFR mutations, especially when used with other therapies, are less understood.
- A study analyzed data from multiple cancer centers for 61 NSCLC patients treated with amivantamab, focusing on factors like response rates, safety, and treatment duration alongside existing therapies.
- Results indicated that 45.2% of patients had a clinical response, with higher success rates in atypical mutation cohorts, and adverse events were consistent with previous findings, suggesting amivantamab's potential effectiveness even in various EGFR mutations when combined with other treatments.
Introduction: amplification is a known resistance mechanism to tyrosine kinase inhibitor (TKI) treatment in -mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefit. Resistance mechanisms to dual EGFR-MET inhibition require further investigation and characterization.
View Article and Find Full Text PDFMutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.
JCO Precis Oncol
January 2023
Purpose: In head and neck squamous cell carcinoma (HNSCC), mutation is a new actionable oncogene driver. We aimed to evaluate mutational variants, comutation profile, and survival outcomes of this molecularly defined population.
Methods: We leveraged four deidentified patient data sets with -mutant HNSCC, MD Anderson Cancer Center, Kura Oncology, Inc trial, Foundation Medicine, and American Association for Cancer Research GENIE v.
Background: The benefit of chemotherapy combined with immunotherapy in EGFR-mutant lung adenocarcinoma (LUAD) patients whose tumor developed resistance to EGFR tyrosine kinase inhibitors (TKIs) is not thoroughly investigated. The goal of this retrospective cohort study is to assess the clinical efficiency of immunotherapy alone or in combination with chemotherapy in a real-world setting.
Methods: This retrospective cohort study enrolled LUAD patients with EGFR sensitive mutations whose tumor had acquired resistance to EGFR TKIs and received systemic treatment with chemotherapy (chemo; = 84), chemotherapy combined with immunotherapy (chemoIO; = 30), chemotherapy plus bevacizumab with or without IO (withBev; = 42), and IO monotherapy (IO-mono; = 22).
Purpose: Neoadjuvant chemotherapy prior to definitive surgery has been utilized widely for locally advanced oral squamous cell carcinoma (OSCC). We evaluated neoadjuvant erlotinib with platinum-docetaxel vs. placebo with platinum-docetaxel in stage III-IVB OSCC patients.
View Article and Find Full Text PDF